Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Penas

Showing results (71-80 of 93) with videos related to

Pageof 10
Sort By:
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Frontiers in Oncology|February 1, 2021
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post ImmunotherapyGuangyang Yu, Madison K Butler, Abdalla Abdelmaksoud, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II TrialShiao-Pei Weathers, Marta Penas-Prado, Be-Lian Pei, et al.
Journal of Neuro-Oncology|March 8, 2023
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trialAmanda L King, Kayla N Roche, Heather E Leeper, et al.
Eclinicalmedicine|November 17, 2022
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyElizabeth Vera, Alexa Christ, Ewa Grajkowska, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Neuro-Oncology Practice|July 19, 2021
Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History StudyJames L Rogers, Elizabeth Vera, Alvina Acquaye, et al.
Pageof 10

Showing results (71-80 of 93) with videos related to

Sort By:
Pageof 10
Neuro-Oncology Advances|April 22, 2026
CERN 09-02: A phase 2 trial of carboplatin and bevacizumab for recurrent adult ependymomasShuodan Zhang, Byram H Ozer, Antonio Omuro, et al.
Cancer Chemotherapy and Pharmacology|October 28, 2017
Efficacy of depatuxizumab mafodotin (ABT-414) monotherapy in patients with EGFR-amplified, recurrent glioblastoma: results from a multi-center, international studyMartin van den Bent, Hui K Gan, Andrew B Lassman, et al.
Neuro-Oncology Advances|April 24, 2026
Combination of metronomic oral pazopanib and topotecan for recurrent glioblastoma with and without previous bevacizumab: Results from a phase 2 clinical trialByram H Ozer, Adam L Cohen, Howard Colman, et al.
Frontiers in Oncology|February 1, 2021
Case Report: Single-Cell Transcriptomic Analysis of an Anaplastic Oligodendroglioma Post ImmunotherapyGuangyang Yu, Madison K Butler, Abdalla Abdelmaksoud, et al.
Neuro-Oncology|July 9, 2018
Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trialAndrew B Lassman, Martin J van den Bent, Hui K Gan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2020
Glioblastoma-mediated Immune Dysfunction Limits CMV-specific T Cells and Therapeutic Responses: Results from a Phase I/II TrialShiao-Pei Weathers, Marta Penas-Prado, Be-Lian Pei, et al.
Journal of Neuro-Oncology|March 8, 2023
Feasibility of a virtual reality intervention targeting distress and anxiety symptoms in patients with primary brain tumors: Interim analysis of a phase 2 clinical trialAmanda L King, Kayla N Roche, Heather E Leeper, et al.
Eclinicalmedicine|November 17, 2022
Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort studyElizabeth Vera, Alexa Christ, Ewa Grajkowska, et al.
Neuro-Oncology|September 21, 2014
Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastomaMarta Penas-Prado, Kenneth R Hess, Michael J Fisch, et al.
Neuro-Oncology Practice|July 19, 2021
Living with a central nervous system (CNS) tumor: findings on long-term survivorship from the NIH Natural History StudyJames L Rogers, Elizabeth Vera, Alvina Acquaye, et al.
Pageof 10